GalChimia

What GalChimia does

GalChimia, S.A. is a privately held Spanish contract research organization founded in 2000 and headquartered in Touro (A Coruña), Spain, that provides organic synthesis and medicinal chemistry services to pharmaceutical, biotechnology, and agrochemical companies. The firm employs between 11 and 50 staff, over 50% of whom hold PhDs, and operates four integrated service lines: Discovery Chemistry (route design and evaluation for new compounds), Process Chemistry (lab-to-pilot scale-up and production optimization), Analytical Services (full characterization and analytical support), and Custom Synthesis (tailored complex molecule synthesis, with demonstrated capability on routes up to 27 steps). Technical capabilities include flow chemistry, biocatalysis, and nanoparticle linker chemistry, with a patent portfolio covering API process chemistry and novel pharmacological scaffolds.

GalChimia commercializes its services through two primary contract models: Fee For Service (FFS) fixed-price contracts for defined compound delivery, and Full Time Equivalent (FTE) programs that allocate dedicated research teams on a monthly billing basis with flexible target adjustment. A third revenue stream consists of licensing royalties from production processes such as Eltrombopag Olamine and Prasugrel Hydrochloride. Customers include enterprise pharmaceutical firms (Almirall, Esteve, Gal-ache, Pangae) and biotech startups (Agomab, Palobiofarma, HQL, Neuron Bio, Vivacel), with more than 95% recurring engagement and a 98% project success rate cited by the company.

The business is sales-led and B2B, with direct engagement via website inquiries, trade show presence at events such as EFMC-ASMC, BIO-Europe Spring, and Swiss Biotech Day, plus content marketing through LinkedIn and a long-running newsletter. GalChimia has expanded its European footprint (Spain, France, Netherlands, Portugal), obtained French CIR research tax accreditation (2014) and Spanish Innovative SME status (2024), and participates in multiple EU-funded R&D consortia including H2020, SHIKIFACTORY100, PRECINMAS (with GSK), NUCAPCURE (with University of Oslo), and MAOPROST. In 2024 the company co-founded the spin-out Iteria Biopharma to develop proprietary oncology drugs, which closed a €5M seed round led by Inveready in April 2026.

Name

GalChimia

Legal name

GalChimia, S.A.

Website

https://galchimia.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

GalChimia is a Spanish contract research organization founded in 2000 that provides organic synthesis, medicinal chemistry, and process chemistry services to pharmaceutical, biotechnology, and agrochemical clients across Europe via FFS and FTE engagement models.

Ownership category

akta.pro rank

Product category

Contract Chemical Synthesis Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

Keywords

• Custom synthesis services
• Medicinal chemistry
• Process chemistry
• Contract research organization
• Drug discovery chemistry

Headquarters

HQ city

A Coruña

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Fee For Service (FFS): Fixed-price contracts for synthesis of specific compounds with clearly defined specifications including raw materials, synthesis, purification, and analytical characterization
2. Full Time Equivalent (FTE): Project-based contracts with dedicated team allocation, ideal for research programs with evolving objectives. Includes full access to analytical platforms and equipment.
3. Licensing Royalties: Licensing of production processes for pharmaceutical products (e.g., Eltrombopag Olamine and Prasugrel Hydrochloride)

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

GalChimia is a European contract research organization (CRO) that delivers custom organic synthesis, medicinal chemistry, process chemistry, analytical characterization, and custom synthesis services to pharmaceutical, biotechnology, and agrochemical companies. Its four core service lines — Discovery Chemistry, Process Chemistry, Analytical Services, and Custom Synthesis — are delivered under two contract engagement models: Fee For Service (FFS) for fixed-scope compound synthesis, and Full Time Equivalent (FTE) for flexible R&D program expansion with dedicated team allocation.

Product overview

GalChimia is a European contract research organization (CRO) specializing in chemical synthesis services for the pharmaceutical and biotech industries. The company offers four integrated core services: Discovery Chemistry (design and development of new synthesis routes), Process Chemistry (lab-to-pilot scale-up and production optimization), Analytical Services (full analytical support and characterization), and Custom Synthesis (tailored complex molecule synthesis). These services are delivered through two contract models: Fee For Service (FFS) for fixed-scope compound delivery with clearly defined specifications, and Full Time Equivalent (FTE) for flexible R&D program expansion. The company maintains over 25 years of expertise with 95%+ customer retention and 98% project success rate.

Differentiator

Problem solved

Functional benefit

Products and services

• Discovery Chemistry Design, evaluation, and development of new routes of synthesis, expanding clients' R&D departments with medicinal chemistry capabilities for drug discovery programs.
• Process Chemistry Scale-up services taking results from lab to pilot plant, optimizing chemical production performance for clients transitioning compounds from research to larger-scale manufacturing.
• Analytical Services Full analytical support and characterization expertise, providing a wide range of analytical techniques for project characterization alongside synthesis services.
• Custom Synthesis Custom design and synthesis of complex molecules tailored to specific client needs, advancing pharmaceutical, biotechnology, and agrochemical projects with confidence.
• Fee For Service (FFS) engagement model Fixed-price contract model for synthesis of specific compounds with clearly defined specifications, including raw materials, synthesis, purification, and analytical characterization. Deliverables include Certificate of Analysis (CoA) and Safety Data Sheet (SDS).
• Full Time Equivalent (FTE) engagement model Project-based contract with dedicated research team allocation for research programs with evolving objectives; includes full access to analytical platforms, purification systems, and chemical equipment, with deliverables of synthesized molecules, CoAs, and comprehensive technical reports.

Quantifiable outcome

• +98% success rate on projects
• +2 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and major.

• Ramon BossercoreStrategic or Co-development Partner · 15 April 2026Co-founder and CEO of Iteria Biopharma. Entrepreneur with experience in biotechnology sector development.
• GSKcoreStrategic or Co-development Partner · 1 January 2025GSK leads the PRECINMAS project - a small molecule AMR project developing pre-candidates with new mechanisms of action against invasive non-typhoidal Salmonella.
• PalobiofarmacoreStrategic or Co-development Partner · 4 December 2024Co-founder of Iteria Biopharma alongside GalChimia and Ramon Bosser. Julio Castro (Palobiofarma CEO) serves as co-founder. Long-term collaborator spanning 20+ years of project work together.
• Iteria BiopharmacoreStrategic or Co-development Partner · 4 December 2024Spin-out biotech company founded by GalChimia, Julio Castro (Palobiofarma), and Ramon Bosser. Focused on development of drugs for treatment of advanced metastatic cancers.
• University of OslocoreStrategic or Co-development Partner · 1 January 2024University of Oslo leads the NUCAPCURE project - targeted radiotherapy for Glioblastoma Multiforme using innovative proton and neutron therapies.
• Esteve QuimicamajorStrategic or Co-development Partner · 1 January 2011Collaboration on CDTI-funded project for development of new routes for generic API synthesis. Worked together on process development for APIs approaching patent expiration.
• Applus+ LGAImajorStrategic or Co-development Partner · 1 January 2011Joint venture GalChimiApplus established to cover process development and large-scale custom synthesis including GMP batches for Phase I clinical trials.
• Vivia BiotechmajorStrategic or Co-development Partner · 1 January 2011Collaboration on HUMANFARMA project for translational drug discovery directly in patient samples. Vivia Biotech led the project financed by the Ministry of Economy and Competitiveness through FEDER.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• ChemPartner: Shanghai-headquartered chemistry CRO offering discovery, process chemistry, and custom synthesis; a closely comparable discovery chemistry peer serving pharma/biotech globally.
• Selvita: Polish CRO offering medicinal chemistry, custom synthesis, and integrated drug discovery; similar European specialty CRO positioning with comparable service lines to GalChimia.
• Sygnature Discovery: UK-based discovery CRO providing medicinal chemistry, in vitro biology, and DMPK services to pharma and biotech; directly comparable to GalChimia's discovery chemistry and custom synthesis offering.
• Concept Life Sciences: UK-based CRO with medicinal chemistry and integrated drug discovery capabilities; comparable specialty discovery CRO serving similar pharma and biotech customers.
• Sai Life Sciences: India-based contract research and manufacturing organization covering discovery chemistry, process R&D, and API manufacturing; comparable in offering custom synthesis and medicinal chemistry services.

Broad incumbents

• Catalent: Global CDMO providing drug development, delivery, and manufacturing solutions; broad incumbent whose chemistry and process development services overlap with GalChimia's custom synthesis and process chemistry.
• Curia (formerly AMRI): Global CDMO offering contract research, API development, and manufacturing services; broad incumbent with chemistry and process development services comparable to GalChimia's.
• Lonza: Swiss CDMO with significant small-molecule and API capabilities; broad incumbent offering process chemistry and scale-up services overlapping with GalChimia's process chemistry and custom synthesis.
• WuXi AppTec: Global CRO/CDMO with extensive chemistry, biology, and manufacturing services; broader incumbent whose discovery chemistry and custom synthesis lines overlap with GalChimia's offerings.
• Eurofins Discovery: European-headquartered discovery services provider offering medicinal chemistry, in vitro pharmacology, and ADME; broad incumbent with adjacent chemistry CRO capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/galchimia-s-l-
• Xx.com/galchimia

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GalChimia